{"id":70419,"date":"2026-07-22T13:46:59","date_gmt":"2026-07-22T05:46:59","guid":{"rendered":"https:\/\/flcube.com\/?p=70419"},"modified":"2026-07-22T13:47:00","modified_gmt":"2026-07-22T05:47:00","slug":"tyk-medicines-and-qilu-pharmaceutical-forge-strategic-partnership-for-egfr-tki-ty-9591-with-2-4b-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70419","title":{"rendered":"TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>TYK Medicines<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2410:HKG\">HKG: 2410<\/a>) and <strong>Qilu Pharmaceutical<\/strong> announced a comprehensive strategic partnership comprising three agreements: a <strong>license and cooperation agreement<\/strong>, a <strong>supply and commercialization agreement<\/strong>, and a <strong>share subscription agreement<\/strong>. The collaboration focuses on the development, production, and commercialization of <strong>TY-9591<\/strong>, a <strong>best-in-class EGFR-TKI<\/strong>, in mainland China, accompanied by a significant equity investment.<\/p>\n\n\n\n<h2 id=\"h-transaction-structure\" class=\"wp-block-heading\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Agreement Type<\/th><th>Key Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>License &amp; Cooperation<\/strong><\/td><td>\u2022 TYK grants Qilu rights to develop\/produce TY-9591 API and commercialize in mainland China<br>\u2022 Upfront payment: <strong>RMB 300 million<\/strong><br>\u2022 Milestone payments: Up to <strong>RMB 2.06 billion<\/strong> upon regulatory approvals and indication expansions<\/td><\/tr><tr><td><strong>Supply &amp; Commercialization<\/strong><\/td><td>\u2022 TYK remains Marketing Authorization Holder (MAH)<br>\u2022 TYK sells products to Qilu-designated distributors<br>\u2022 TYK pays promotion fees to Qilu for marketing services<\/td><\/tr><tr><td><strong>Share Subscription<\/strong><\/td><td>\u2022 Qilu subscribes to <strong>63,222,744 H-shares<\/strong> (16.63% stake)<br>\u2022 Price: <strong>HKD 7.30 per share<\/strong><br>\u2022 Total equity investment: <strong>RMB 400 million<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-ty-9591\" class=\"wp-block-heading\">Product Profile \u2013 TY-9591<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Highly selective, irreversible <strong>EGFR tyrosine kinase inhibitor<\/strong> (EGFR-TKI)<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Demonstrated <strong>best-in-class potential<\/strong> in multiple clinical studies<\/li>\n\n\n\n<li><strong>Origin:<\/strong> Independently developed by <strong>TYK Medicines<\/strong><\/li>\n\n\n\n<li><strong>Target Market:<\/strong> Mainland China oncology market<\/li>\n\n\n\n<li><strong>Therapeutic Area:<\/strong> EGFR-mutated cancers (specific indications to be expanded)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-impact\" class=\"wp-block-heading\">Financial Impact<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The transaction represents one of the largest biopharmaceutical partnerships in China&#8217;s oncology sector:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Potential Value:<\/strong> <strong>RMB 2.76 billion<\/strong> (approximately <strong>US$384 million<\/strong>)<\/li>\n\n\n\n<li>Upfront: RMB 300 million<\/li>\n\n\n\n<li>Milestones: RMB 2.06 billion<\/li>\n\n\n\n<li>Equity Investment: RMB 400 million<\/li>\n\n\n\n<li><strong>Equity Stake:<\/strong> Qilu acquires <strong>16.63% ownership<\/strong> in TYK Medicines<\/li>\n\n\n\n<li><strong>Revenue Model:<\/strong> TYK retains MAH status while leveraging Qilu&#8217;s commercial infrastructure<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale\" class=\"wp-block-heading\">Strategic Rationale<\/h2>\n\n\n\n<h3 id=\"h-for-tyk-medicines\" class=\"wp-block-heading\">For TYK Medicines<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Acceleration:<\/strong> Access to Qilu&#8217;s extensive distribution network and promotional capabilities in China<\/li>\n\n\n\n<li><strong>Capital Infusion:<\/strong> Significant upfront and milestone payments to fund global development programs<\/li>\n\n\n\n<li><strong>Strategic Validation:<\/strong> Partnership with established Chinese pharmaceutical leader validates TY-9591&#8217;s best-in-class profile<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-qilu-pharmaceutical\" class=\"wp-block-heading\">For Qilu Pharmaceutical<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovative Pipeline Addition:<\/strong> Gains access to a best-in-class EGFR-TKI with strong clinical data<\/li>\n\n\n\n<li><strong>Oncology Portfolio Enhancement:<\/strong> Strengthens position in targeted cancer therapies<\/li>\n\n\n\n<li><strong>Equity Upside:<\/strong> Meaningful ownership stake in a high-growth biotech company<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The EGFR-TKI market in China represents substantial commercial opportunity:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EGFR Mutation Prevalence:<\/strong> Approximately <strong>40-50%<\/strong> of non-small cell lung cancer (NSCLC) patients in Asia harbor EGFR mutations<\/li>\n\n\n\n<li><strong>Market Size:<\/strong> China&#8217;s EGFR-TKI market projected to exceed <strong>RMB 10 billion<\/strong> annually by 2030<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Intense competition among third-generation EGFR-TKIs drives demand for best-in-class profiles<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-company-profiles\" class=\"wp-block-heading\">Company Profiles<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>TYK Medicines<\/strong> (HKG: 2410) is a Hong Kong-listed biopharmaceutical company focused on developing innovative oncology therapeutics with global potential.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Qilu Pharmaceutical<\/strong> is a leading Chinese pharmaceutical company with extensive commercial infrastructure, manufacturing capabilities, and market presence across therapeutic areas.<\/p>\n\n\n\n<h2 id=\"h-implementation-timeline\" class=\"wp-block-heading\">Implementation Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate:<\/strong> Equity subscription completion and upfront payment<\/li>\n\n\n\n<li><strong>Near-term:<\/strong> Initiation of API development and production activities<\/li>\n\n\n\n<li><strong>Ongoing:<\/strong> Regulatory submissions and commercial preparation<\/li>\n\n\n\n<li><strong>Long-term:<\/strong> Milestone achievement tied to regulatory approvals and indication expansions<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership implementation, regulatory approvals, and financial expectations. Actual results may differ due to risks including regulatory decisions, clinical outcomes, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072100920_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026072100920_c.\"><\/object><a id=\"wp-block-file--media-a856d45c-1500-4d3d-ab4b-96800780957f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072100920_c.pdf\">2026072100920_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072100920_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a856d45c-1500-4d3d-ab4b-96800780957f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TYK Medicines (HKG: 2410) and Qilu Pharmaceutical announced a comprehensive strategic partnership comprising three agreements:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1586,208,33,395],"class_list":["post-70419","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-2410","tag-qilu-pharmaceutical","tag-tkis-egfr-vegf-btk-etc","tag-tyk-medicines"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"TYK Medicines (HKG: 2410) and Qilu Pharmaceutical announced a comprehensive strategic partnership comprising three agreements: a license and cooperation agreement, a supply and commercialization agreement, and a share subscription agreement. The collaboration focuses on the development, production, and commercialization of TY-9591, a best-in-class EGFR-TKI, in mainland China, accompanied by a significant equity investment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70419\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal\" \/>\n<meta property=\"og:description\" content=\"TYK Medicines (HKG: 2410) and Qilu Pharmaceutical announced a comprehensive strategic partnership comprising three agreements: a license and cooperation agreement, a supply and commercialization agreement, and a share subscription agreement. The collaboration focuses on the development, production, and commercialization of TY-9591, a best-in-class EGFR-TKI, in mainland China, accompanied by a significant equity investment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70419\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-22T05:46:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-22T05:47:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70419#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70419\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal\",\"datePublished\":\"2026-07-22T05:46:59+00:00\",\"dateModified\":\"2026-07-22T05:47:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70419\"},\"wordCount\":483,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2410\",\"Qilu Pharmaceutical\",\"TKIs (EGFR VEGF BTK etc.)\",\"TYK Medicines\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70419#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70419\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70419\",\"name\":\"TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-22T05:46:59+00:00\",\"dateModified\":\"2026-07-22T05:47:00+00:00\",\"description\":\"TYK Medicines (HKG: 2410) and Qilu Pharmaceutical announced a comprehensive strategic partnership comprising three agreements: a license and cooperation agreement, a supply and commercialization agreement, and a share subscription agreement. The collaboration focuses on the development, production, and commercialization of TY-9591, a best-in-class EGFR-TKI, in mainland China, accompanied by a significant equity investment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70419#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70419\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70419#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal - Insight, China&#039;s Pharmaceutical Industry","description":"TYK Medicines (HKG: 2410) and Qilu Pharmaceutical announced a comprehensive strategic partnership comprising three agreements: a license and cooperation agreement, a supply and commercialization agreement, and a share subscription agreement. The collaboration focuses on the development, production, and commercialization of TY-9591, a best-in-class EGFR-TKI, in mainland China, accompanied by a significant equity investment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70419","og_locale":"en_US","og_type":"article","og_title":"TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal","og_description":"TYK Medicines (HKG: 2410) and Qilu Pharmaceutical announced a comprehensive strategic partnership comprising three agreements: a license and cooperation agreement, a supply and commercialization agreement, and a share subscription agreement. The collaboration focuses on the development, production, and commercialization of TY-9591, a best-in-class EGFR-TKI, in mainland China, accompanied by a significant equity investment.","og_url":"https:\/\/flcube.com\/?p=70419","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-22T05:46:59+00:00","article_modified_time":"2026-07-22T05:47:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70419#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70419"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal","datePublished":"2026-07-22T05:46:59+00:00","dateModified":"2026-07-22T05:47:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70419"},"wordCount":483,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2410","Qilu Pharmaceutical","TKIs (EGFR VEGF BTK etc.)","TYK Medicines"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70419#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70419","url":"https:\/\/flcube.com\/?p=70419","name":"TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-22T05:46:59+00:00","dateModified":"2026-07-22T05:47:00+00:00","description":"TYK Medicines (HKG: 2410) and Qilu Pharmaceutical announced a comprehensive strategic partnership comprising three agreements: a license and cooperation agreement, a supply and commercialization agreement, and a share subscription agreement. The collaboration focuses on the development, production, and commercialization of TY-9591, a best-in-class EGFR-TKI, in mainland China, accompanied by a significant equity investment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70419#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70419"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70419#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70419"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70419\/revisions"}],"predecessor-version":[{"id":70421,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70419\/revisions\/70421"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}